AI Article Synopsis
- The study evaluated how patient cost-sharing affects adherence to oral diabetes medications and overall glycemic control.
- A retrospective observational approach was used, analyzing medical claims and electronic medical records from a managed care plan in Oregon.
- Findings indicated that as patient cost share increased, adherence to medication decreased, leading to poorer glycemic control, highlighting the need for employers and insurers to reconsider cost-sharing strategies.
Article Abstract
Purpose: To evaluate the effect of patient cost-sharing on oral diabetes medication adherence and glycemic control.
Design: Retrospective observational study.
Methodology: Medical and pharmacy claims from a managed care plan and electronic medical records (EMR) from a large physician organization in Oregon were used to identify a cohort with diabetes. Medication adherence and mean patient cost share was obtained from claims. Glycosylated hemoglobin (A(1c)) values were obtained from an EMR database.
Principal Findings: Lower mean cost share for patients was associated with higher medication adherence. Each $5 increase in patient cost share resulted in a 15 percent decrease in the adjusted odds of being adherent and a 0.1 percentage point increase in A(1c).
Conclusion: Increased medication cost share resulted in a decrease in adherence and poorer glycemic control. Employers and insurers should consider the potential consequences of increased medication cost share on diabetes-related outcomes and health care costs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Health behavior and medical insurance under the healthy China strategy: a moral hazard perspective.
Front Public Health
January 2025
School of Economics and Management, Huzhou University, Huzhou, China.
Introduction: High medical expenditure is one of the major obstacles to achieving common prosperity in China. As a health risk compensation and protection mechanism, medical insurance has played a good role in alleviating the economic burden of patients. However, due to the existence of moral hazard, medical insurance may also lead to the occurrence of psychological deviation and overtreatment of patients or hospitals' health treatment expectations, thus generating unnecessary pressure on public financial expenditure.
View Article and Find Full Text PDFExploring adaptive health technology assessment for evaluating 10 cancer interventions: insights and lessons from a pilot study in India.
BMJ Evid Based Med
January 2025
Center for Global Development, Washington, District of Columbia, USA.
Background: Health technology assessment (HTA) is a valuable tool for informing the efficient allocation of resources in healthcare. However, the resource-intensive nature of HTA can limit its application, especially in low-resource settings. Adapting HTA processes by assessing the available international evidence offers a pragmatic approach to provide evidence for decision-making where resources are constrained.
View Article and Find Full Text PDFA systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.
PLoS One
January 2025
School of Mathematics, Manchester University, Manchester, United Kingdom.
The genus Neisseria includes two major human pathogens: N. meningitidis causing bacterial meningitis/septicemia and N. gonorrhoeae causing gonorrhoea.
View Article and Find Full Text PDFBudget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States.
J Manag Care Spec Pharm
January 2025
Global Value and Real-World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ.
Background: Bipolar disorder is a severe recurrent, episodic psychiatric condition with a worldwide prevalence of approximately 1%, affecting more than 5 million adults in the United States in 2020. A subtype, bipolar I disorder (BP-I), which accounts for approximately one-quarter of cases, is associated with impairments in psychosocial functioning and quality of life. Recommended treatment options include daily oral, or long-acting injectable, antipsychotics, including the aripiprazole once every month formulation, which has been shown to improve adherence compared with oral treatments.
View Article and Find Full Text PDFBudget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States.
J Manag Care Spec Pharm
January 2025
Global Value and Real-World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ.
Background: Schizophrenia is a chronic psychiatric disorder, affecting 1.1% of the adult population in 2020 in the United States. Antipsychotic treatment is commonly used in schizophrenia management to help reduce the likelihood of symptom recurrence and relapse.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!